Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an investigational fecal microbiota transplantation (FMT) being evaluated in a clinical trial at Soroka University Medical Center. [1-9, 3-8] The therapy consists of capsules containing fecal microbiota from donors who have completely responded to immunotherapy. [1-15] It is being studied for its safety and efficacy in enhancing the response to standard first-line immunotherapy, with or without chemotherapy, in patients with metastatic lung cancer. [1-9, 1-13, 3-8] The aim is to modulate the gut microbiome to improve the disease control rate. [1-14] The treatment is administered orally in capsules at the start of each (chemo-)immunotherapy cycle. [1-1, 1-2] The Phase 2 trial is registered as NCT05502913 and is funded by the Israel Cancer Association. [1-3, 1-20]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fecal microbiota transplantation (Soroka University Medical Center).